login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Convergent procedure building support for interdisciplinary approach to atrial fibrillation


Tuesday, 05 Jun 2012 15:37
Borut Gersak
Borut Gersak


nContact has announced that an article was recently published in the Journal of Cardiovascular Electrophysiology chronicles the development of an new interdisciplinary approach for the treatment of atrial fibrillation, the convergent procedure, and illustrates the strong success of the site’s programme. Outcomes were determined by the most stringent methodology, 24-hour loop recorders, which demonstrated unparalleled success in this patient cohort. Physician reaction to the paper has been positive.


Lead author of the paper, Borut Gersak, chief of Cardiac Surgery, University Medical Center, Ljubljana, Slovenia, said: “This paper may be reviewed in hindsight as a pivotal paper in determining the true standard for success of an ablation procedure. The paper documents the evolution of a closed chest, truly minimally invasive interdisciplinary procedure, the Convergent Procedure, its early challenges and lessons learned, the protocols developed to improve and insure clinical safety, and the successful patient experience as monitored by a continuous loop recorder, Medtronic’s Reveal XT. The convergent procedure has proven itself under today’s most stringent monitoring standards, and sets a new and higher standard for clinical and patient outcome success.”

Kenneth Civello, cardiac electrophysiologist, Our Lady Of The Lake Regional Medical Center, Baton Rouge, Louisiana, USA, said: “The data is impressive, and the results are consistent with results we have obtained utilizing the Convergent Procedure in our hospital, and abstracts presented at Boston AF Symposium and the Heart Rhythm Society Scientific Sessions (HRS). This is important because the procedure can be standardised to obtain consistent results among a variety of sites. The results with patients in sinus rhythm off anti-arrhythmic drugs (AADs) of 74% are even more impressive because 94% of the patients were persistent or long standing persistent patients. HRS defines catheter outcome success as ’freedom from AF and off AADs at 40%’ for persistent patients and 30% for long standing persistent patients.”

Paul Mounsey, chief of Electrophysiology, University of North Carolina Hospital, Chapel Hill, North Carolina, USA, said: “This is an important paper because the Convergent Procedure addresses atrial fibrillation in a scientific manner by addressing both endocardial and epicardial substrates in a comprehensive anatomic approach. Its success can be related back to the large body of literature on lesion patterns, lesion completeness, substrate activation, anatomical remodeling, atrial stretch, and atrial function. This is not a potential magical silver bullet, but rather the use of an increasingly relevant and rapidly growing ablation technology to augment existing strategies.”

 




Add New Comment

Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

St Jude Medical MultiPoint Pacing Technology could achieve 87% patient response rate according to clinical trial
Thursday, 05 May 2016
Results of St Jude Medical’s MultiPoint Pacing investigational device exemption clinical study have been presented during a late-breaking clinical trial session at the Heart Rhythm Society’s (HR... St Jude Medical MultiPoint Pacing Technology could achieve 87% patient response rate according to clinical trial

European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices
Tuesday, 31 May 2016
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ... European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices

Features


The challenge of monitoring innovation in modern electrophysiology beyond randomised controlled trials: Time for a cultural shift
Thursday, 09 Jun 2016
We now live in an unprecedented era of technological advances, which is eclipsing our ability to test new therapies at the pace of these advances and the natural history of most heart rhythm ... The challenge of monitoring innovation in modern electrophysiology beyond randomised controlled trials: Time for a cultural shift

Stent-based technology shows promise in isolating pulmonary veins in pre-clinical study
Wednesday, 01 Jun 2016
Pre-clinical data, presented at the 13th International Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy (IDSS; 6–9 March, Tel Aviv, Israel), have shown that it is feasible ... Stent-based technology shows promise in isolating pulmonary veins in pre-clinical study

Profiles


Etienne Aliot
Wednesday, 08 Jun 2016
Etienne Aliot (Nancy, France) has always been fascinated by the work of surgeons. This fascination ... Etienne Aliot

George Van Hare
Wednesday, 04 May 2016
George Van Hare (The Louis Larrick Ward professor of Pediatrics and director, Division of Pediatric ... George Van Hare

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions